
EMR · NYSE
Consensus is Buy across 22 analysts, with a reported mean price target of $164. The supplied data provide no low or high target, so target clustering and the width of the target spread cannot be measured. No named analyst is identified as the most or least bullish, and no firm-specific rating or target revisions are reported during the week; the direction of revisions is therefore unavailable. The substantive disagreement behind any target dispersion is also not documented in the evidence. The available operating debate centers instead on whether automation strength and the third-quarter earnings beat can outweigh cost pressures tied to the AspenTech buyout.